All articles

To Get Wet-AMD Gene Therapy To Finish Line 4DMT Reduces Workforce By 25%

Biogen To Move Salanersen Forward As Alternative SMA Therapy To ZOLGENSMA Non Responders

Nektar’s Rezpeg Hopes Revived After Latest Atopic Dermatitis Treatment Data

Merck Gets RSV Vaccine Approval From FDA Pitting It Against Beyfortus

Otsuka Sibeprenlimab Achieves Impressive Proteinuria Reduction In IgAN Patients

Despite Phase 2 Trial Failure In ALSP For Vigil, Sanofi Acquisition Still On Right Track

MoonLake Sought Out For By Merck For $3 Billion To Add Sonelokimab To Arsenal, FT Reports

PD-1/VEGF Market Heats Up With Bristol-Myers Squibb And BioNTech $11.1B Tie-Up

Scroll to Top